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Abstract 
Multidrug resistance tuberculosis (MDR-TB) is a serious concern in the public health 
environment globally and the understanding of its mechanisms may help to prevent the 
emergence and spread of resistant strains of Mycobacterium tuberculosis (Mtb). Several 
compounds are being tested in clinical trials and SQ109 was identified as a promising new 
anti-TB drug because of its bactericidal activity against Mtb and demonstrated synergistic 
activity with the fist-line TB drugs. This study focussed on the mechanism of synergy of 
SQ109 with rifampicin (RIF) and isoniazid (INH) in Mycobacterium smegmatis (Msmeg). The 
influence of SQ109 on efflux in Msmeg was evaluated using two approaches. Firstly, 
accumulation and efflux of ethidium bromide (EtBr) was monitored using a semi-automated 
fluorometric assay and secondly efflux and accumulation of RIF in Msmeg was assessed 
using tandem mass spectrometry. Although SQ109 resulted in a slight decrease in EtBr efflux 
by Msmeg in some of the assays performed, this decrease was not consistently seen. SQ109 
appeared to have no significant influence on the efflux or accumulation of RIF in Msmeg, 
suggesting that it does not act to inhibit efflux in this organism. Six spontaneous SQ109-
resistant mutants were generated in Msmeg and bactericidal activity of SQ109, RIF and INH 
against wild-type and mutant strains of Msmeg was assessed. The minimum inhibitory 
concentrations (MICs) for all three drugs increased in the mutant strains compared to the 
wild-type. Drug-drug interaction studies performed on one of the SQ109-resistant mutants 
revealed a change from synergy to additivity for both SQ109/RIF and SQ109/INH 
combinations, suggesting that identification of the genes harbouring mutations in these 
strains would shed light on the mechanism of synergy of SQ109 with RIF and INH. Sanger 
sequencing revealed that none of the SQ109-resistant mutants harboured mutations in 
MSMEG_0250 (mmpL3 homologue), a gene previously implicated in SQ109 resistance in M. 
tuberculosis. Preliminary whole genome sequencing data for six SQ109-resistant mutants 
identified SNPs in 10 genes, however the role of these genes in SQ109 resistance and 
synergy with RIF and INH in Msmeg remains to be verified. 
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Opsomming 
 
Multi-middel weerstandige tuberkulose (MDR-TB) is ‘n ernstige probleem in globale 
publieke gesondheid. Kennis van die meganisme van middelweerstandigheid kan help om 
die ontwikkeling en versprei van weerstandige Mycobacterium tuberculosis (Mtb) te 
voorkom. Verskeie middele word tans in kliniese proewe getoets. SQ109 is identifiseer as ‘n 
belowende nuwe anti-TB middel as gevolg van die kiemdodende aktiwiteit wat dit teen Mtb 
toon en die sinergistiese aktiwiteit wat dit met die eerstelyn TB middele toon. Hierdie studie 
fokus op die meganisme van sinergie van SQ109 met rifampisien (RIF) en isoniasied (INH) in 
Mycobacterium smegmatis (Msmeg). Twee benaderings is gebruik om die invloed van 
SQ109 op effluks in Msmeg te evalueer. Eerstens is opbou en effluks van ethidium bromied 
(EtBr) gemonitor deur van ‘n semi-outomatiese fluorometriese toets gebruik te maak. 
Tweedens is effluks en opbou van rifampicin (RIF) in Msmeg ondersoek deur van tandem 
massaspektrometrie gebruik te maak. Alhoewel SQ109 ‘n effense afname in EtBr effluks in 
Msmeg in sommige van die eksperimente veroorsaak het, is die afname nie herhaaldelik 
deur al die eksperimente gesien nie. Dit het geblyk dat SQ109 geen beduidende invloed op 
effluks of opbou van RIF in Msmeg gehad het nie, wat daarop dui dat dit nie as ‘n effluks 
inhibeerder in die organisme optree nie. Ses spontane SQ109 weerstandige mutante is in 
Msmeg gegenereer en die kiemdodende aktiwiteit van SQ109, RIF en INH teen die wilde-
tipe en mutante is ondersoek. Die minimum inhiberende konsentrasie (MIC) vir al drie 
middels is verhoog in die mutante in vergelyking met die wilde-tipe. Middel-middel 
interaksie studies uitgevoer vir een van die SQ109 weerstandige mutante het getoon dat 
daar ‘n verandering van sinergie to additiwiteit vir beide SQ109/RIF en SQ109/INH 
kombinasies was. Dit het voorgestel dat die identifisering van gene waarin mutasies 
voorkom in die SQ109 mutante kan lei tot die identifisering van die meganisme van sinergie 
van SQ109 met RIF en INH. Sanger DNA volgordebepaling het getoon dat geen van die 
SQ109 mutante mutasies in die MSMEG_0250 (mmpL3 homoloog), ‘n geen wat voorheen 
geassosieer is met SQ109 weerstandigheid in M. tuberculosis, gehad het nie. Met voorlopige 
heel genoom volgorde bepaling vir die ses SQ109 mutante is SNPs in 10 gene identifiseer, 
maar die rol van die gene in SQ109 weerstandigheid en sinergie met RIF en INH in Msmeg 
moet verifieer word. 
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Chapter 1 
   Literature review 
 
1.1 Tuberculosis 
TB (tuberculosis) is one of the infectious diseases in the world that causes ill-health among 
millions of people each year and ranks as the second leading cause of death from an 
infectious disease worldwide, after the human immune-deficiency virus (WHO 2014). In 
1882, Robert Koch identified Mycobacterium tuberculosis (Mtb) as the causative agent of 
tuberculosis by isolating it from infected individuals and visualised the bacilli microscopically 
using acid-fast staining. 
Morbidity and mortality rates due to TB steadily dropped during the 20th century in the 
developed world, aided by better public health practices and widespread use of the 
Mycobacterium bovis BCG vaccine, as well as the development of antibiotics in the 1950s. 
This downward trend ended and the number of new cases started increasing in the mid-
1980s. The major causes of this increase were homelessness and poverty in the developed 
world and the emergence of AIDS, with its destruction of the cell-mediated immune 
response in co-infected persons (Smith 2003). 
Mtb belongs to the complex of mycobacteria that cause TB in either humans or animals. The 
Mtb complex consists of different species of mycobacteria including M. tuberculosis, M. 
cannettii, M. bovis, M. africanum, M. microti, M. caprae, and M. pinnipedii. M. tuberculosis, 
M. africanum and M. cannettii are human pathogens, while the rest of the species are 
pathogenic to animals (Smith 2003). 
1.2 The natural history of tuberculosis infection 
Tuberculosis is a communicable disease and is spread by airborne particles called droplets 
nuclei, which are particles of 1-5 microns in diameter.  
The droplet nuclei can remain airborne for several minutes to hours after expectoration 
(Smith 2003; Ahmad 2010). Several factors determine the risk of infection such as the 
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immune status of the exposed individual, the bacillary load inhaled, the proximity, the 
frequency and the duration of exposure (Smith 2003). 
When an inhaled droplet containing tubercle bacilli reach the alveoli of the lungs they are 
engulfed by alveolar macrophages where the majority of bacilli are killed. A small number of 
bacilli may replicate intracellularly, and are released when death of macrophages occurs 
(Korf et al.et al. 2005). These bacilli may cross the alveolar membrane to cause systemic 
dissemination and spread to more distant tissues and organs such as kidneys, brain, larynx, 
lymph node, lung, spine and bone (Schluger 2005).  
In the majority of people infected with Mtb an effective cell-mediated immune response 
develops 2-8 weeks after infection, which stops further replication of the bacilli. The 
activated macrophages, T lymphocytes and other immune cells form a barrier shell called a 
granuloma that limits further multiplication and spread of the bacilli. Most of the Mtb are 
killed in the caseating granulomas, however the pathogen is not completely eliminated in 
some people but rather controlled by the immune system. This is the latent tuberculosis 
infection (LTBI), where individuals are asymptomatic (Ahmad 2010). Viable bacilli may 
persist in the necrotic material for years or even a lifetime, and if the immune system later 
becomes compromised, the bacilli begin to replicate rapidly and active tuberculosis 
develops (TB disease). The disease manifests mainly in the lungs, but the process can occur 
in other areas of the body (extra pulmonary TB). Several factors are involved in reactivation 
of latent infection, including uncontrolled diabetes mellitus, malnutrition, smoking, renal 
failure, organ transplantation, and therapy with immunosuppressive drugs. HIV infection 
causes depletion of CD4+ and CD8+ T-cells which provide protection (Walzl et al. 2011; 
Dartois 2014)  against active TB by modulating phagocyte activity (Ahmad 2010; Walzl et 
al.et al. 2011), and is the most important factor for reactivation when co-infection occurs. 
1.3 Treatment of Tuberculosis 
Standard chemotherapy for drug sensitive TB consists of an intensive phase in which 
patients receive INH, RIF, PZA and EMB for two months, and a continuation phase of four 
months during which only  isoniazid (INH) and rifampicin (RIF) are administered (WHO 
2006). As the drugs have different targets within the bacilli, the combination of antibiotics 
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prevents the development of TB drug-resistance (Kremer and Besra 2002; Nikonenko et al. 
2007; Palomino and Martin 2014)  
In case of multidrug–resistant tuberculosis (MDR-TB), defined as resistance to both RIF and 
INH, the second-line drugs are used, namely the fluoroquinolones (ofloxacin, ciprofloxacin, 
levofloxacin or moxifloxacin) and the aminoglycosides (kanamycin, amikacin, capreomycin, 
ethionamide, and cycloserine). These drugs are generally less effective or more toxic 
(Blumberg et al. 2003). Extensively drug resistant tuberculosis (XDR-TB) is defined as MDR-
TB plus resistance to fluoroquilones and at least to one of the aminoglycosides. XDR-TB is 
managed by using the third-line drugs such as linezolid, clofazimin, amoxicillin and 
clarithromycin (Prozorov et al. 2012). Recently some Mtb strains have been found resistant 
even to the third-line drugs or to all known TB drugs (Migliori et al. 2012). 
1.4 Tuberculosis drug resistance 
The emergence of drug resistance is one of the major problems for eradicating TB 
worldwide. Cases of MDR-TB and XDR-TB are being found in many countries and strategies 
such as utilising new drug combinations and the discovery of new drugs are required to 
ensure the future success of TB control programmes (Raman et al. 2008). The intrinsic 
resistance of Mtb to several antibiotics is a result of the low permeability of bacteria to 
different drugs, the stimulation of the efflux pumps and the inactivation of drugs by certain 
enzymes (Silva and Palomino 2011). Besides these, the acquisition of drug resistance occurs 
as a result of chromosomal mutations (Zhang and Yew 2009; Raja et al. 2011; Prozorov et al. 
2012). These mutations result in resistance by preventing the binding of the drug to its 
specific target or drug-modifying enzyme due to a change in structure, or by altering the 
expression of the drug target or modifying enzyme (Prozorov et al. 2012). In the genome of 
Mtb, mutations occur spontaneously and frequencies have been estimated to be 3.5 x 10-6 
for INH and 3.1 x 10-8 for RIF. The molecular mechanisms of resistance to TB drug is 
associated with gene mutations in specific regions. For example 95% of all RIF resistances 
are associated with mutations in an 81 bp region of the rpoB gene while 80% of mutations 
confer resistance to INH occur in codon 315 of the katG gene (Raman et al. 2008; Raja et al. 
2011). The table 1.1 below shows current drugs used in TB treatment, their mechanisms of 
action and the genes involved in the mechanisms of resistance. 
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1.5 Modulating intracellular drug concentration as a mechanism of altering drug 
sensitivity 
1.5.1 The mycobacterial cell wall 
Mycobacteria are surrounded by a cell wall with the unique structural and functional 
characteristics and rich in lipid compounds. The mycobacterial cell wall is composed of a 
covalently associated complex of three structures: peptidoglycan, arabinogalactan, and 
mycolic acids and form the mycobacterial cell wall skeleton or the mycolyl-arabinogalactan-
peptidoglycan complex (MAPc) (Crick et al. 2001). The MAPc is an ideal target for drug 
development and currently many compounds in use or in clinical trials inhibit the 
biosynthesis of cell wall structure (Crick et al. 2001; Hett and Rubin 2008).  
The mycobacterial cell envelope can be divided into two main structural components, 
namely the cell membrane and cell wall. The outer leaflet of the cell wall is formed with the 
mycolic acids which are covalently attached to the arabinogalactan-peptidoglycan complex 
of the inner leaflet. The cell envelope of mycobacteria is unique in that besides the cell 
membrane and peptidoglycan layers, it also contains distinctive lipids and glycolipids that 
confer extreme hydrophobicity to the outer surface (Korf et al. 2005). Several cell wall 
components of Mtb have been identified as pathogen-associated molecular pattern (PAMP), 
including the glycolipid lipoarabinomannan (LAM) (Andries et al. 2005; Tahlan et al. 2012). 
The unique structure of the cell wall plays a significant role in drug resistance as a barrier to 
the entry of drugs into the cell, which diminishes the accumulation of intracellular drugs 
while efflux mechanisms also contribute as an important factor in anti-TB resistance in Mtb 
such as fluoroquinolones, tetracyclines and amimoglygosides (Louw et al. 2009; Nikaido 
2009). 
1.5.2 Transport across the mycobacterial cell wall  
Most molecules of biological origin are transported across the cellular membrane in a 
process that involves specific and specialised transport proteins such as porins, drug 
importers and efflux pumps (Hett and Rubin 2008; Grzegorzewicz et al. 2012; Chao et al. 
2013). There are three types of transport operating across the cell envelope to move 
substances or chemotherapeutic agents in and out of the cell wall, namely passive 
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transport, facilitated transport and active transport. The first two processes of transport 
employ the power of diffusion and do not require any energy for transporting substances 
across the cell wall. 
1.5.3 Passive transport 
Passive transport is the moving of substances across cell membrane without the use of 
energy, this mechanism of transport includes simple diffusion, facilitated diffusion, and 
osmosis. Simple diffusion is the process by which small uncharged molecules, such as 
oxygen (O2) and carbon dioxide (CO2) easily permeate over the cell membrane from the 
higher concentration areas to the lower concentration areas. Osmosis is the diffusion of 
water through a semi-permeable membrane from the higher concentration areas to the 
lower concentration areas (Sarathy et al. 2012). 
Facilitated transport is a form of diffusion that allows transport of substances or molecules 
through the cell membrane without requiring energy consumption. Substances or molecules 
across a membrane pass spontaneously through specific transmembrane transport proteins 
during this diffusion. This uptake pathway involves a limited range of compounds since 
channel diameters at the narrowest point define the exclusion limit, and other parameters 
such as the length of channels and the number of open pores that determine the speed of 
transport. A number of porins have been identified and studied in Gram-negative and Gram-
positive bacteria and two putative classes have been characterised in mycobacteria; MapA-
like and OmpA-like pores in M. smegmatis and M. tuberculosis respectively (Sarathy et al. 
2012). 
MspA was the first porin to be identified in mycobacteria, previous studies have 
documented MspA-enabled transport of hydrophilic solutes and drug molecules across the 
cell membrane. The genome of M. smegmatis has revealed three more porin genes 
homologous to mspA, namely mspB, mspC and mspD and the studies showed that the 
deletion of porins is linked to increases in MICs of various antibiotics (Li and Nikaido 2009; 
Sarathy et al. 2012; Amaral et al. 2014). In several instances the increase in MICs has been 
associated with reduction in drug uptake in M. smegmatis. 
OmpATb was the first porin-like identified in Mtb and this porin is encoded by the Rv0899 
gene. OmpATb plays a key role in conferring Mtb the ability to survive under acidic 
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environment. The deletion mutant in OmpATb exhibits a significant reduction in 
permeability to a number of hydrophilic molecules and impaired ability to grow at reduced 
pH. 
1.5.4 Active transport 
Active transport requires energy to transport substances or molecules across the cell 
membrane. The ATP used in active transportation may be used directly; when transporters 
bind ATP and use the energy of its hydrolysis to transport molecules against a concentration 
gradient, or indirectly, when ATP is used to generate a proton gradient. Active transport is 
further divided into two processes namely influx and efflux. 
1.5.4.1 Influx transporters  
In mycobacteria, the influx of toxic compounds is significantly restricted by the complex cell 
and lipid bilayer. Influx is the physiological mechanism that allows molecules to enter the 
cell by crossing the bacterial envelope. These influx transporters are proteins localized in the 
cell wall and selectively import molecules into the cell.  
1.5.4.2 Efflux pumps  
Bacterial efflux pumps are located in the cell membrane and are associated with 
antimicrobial resistance. Efflux pumps are transporter proteins that promote the extrusion 
of molecules out of the cell as they enter. The physiological role of these pumps is the 
extrusion of noxious agents from the cell, allowing the bacteria to survive in a hostile 
environment (Poole 2007). Recently it has been recognised that efflux pumps also play a 
role in altering the sensitivity of mycobacteria to drugs (Adams et al. 2011; Stephan et al. 
2004). Genes encoding drug efflux transporters have been identified in the genome of 
several mycobacteria. These proteins have been implicated in the transport of a number of 
drugs such as tetracycline, fluoroquilones, aminoglycosides, rifampicin and isoniazid (De 
Rossi et al. 2006). 
Efflux pumps in bacteria differ structurally and in their mode of action are classified into five 
families based on their bio energetic and structural characteristics, namely: the ATP-binding 
cassette (ABC) superfamily; the major facilitator superfamily (MFS); the multidrug and toxic 
compound extrusion (MATE) family; the small multidrug resistance (SMR) family; and the 
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resistance nodulation division (RND) family. Efflux pumps that belong to the ABC 
superfamily are considered primary active transporters because they utilize the free energy 
of ATP hydrolysis to extrude drugs out of the cell. The other families of efflux pumps are 
called secondary active transporters because they use the proton or sodium ions as a source 
of energy to extrude the drugs from the cell (Omote et al. 2006). 
o ATP –binding cassette (ABC) superfamily 
The ABC transporters have an ATP hydrolysis mechanism involved in the extrusion of various 
molecules such as toxins, metabolites and drugs from the cell. ABC transporters appear to 
consist of four domains: two membrane-spanning domains (MSDs) and two nucleotide-
binding domains (NBDs). The nucleotide binding domains are highly homologue and possess 
the walker A and walker B motifs which are common to all ATP-binding proteins. Genes 
encoding ABC transporters occupy 2.5% of the M. tuberculosis genome, based on structural 
similarities to the subunits of ABC transporters present in all living organisms, at least 37 
complete and incomplete have been identified in M. tuberculosis (Braibant et al. 2000). 
o Major facilitator superfamily (MFS) 
The MFS is a large superfamily of membrane transporters and are present in all organisms. 
MFS possess 12 or 14 putative transmembrane segments and are involved in the transport 
of many different compounds such as simple sugars, oligosaccharides, amino acids, drugs, 
nucleosides and Krebs cycle metabolites. The MFS contains several important efflux pumps, 
like QacA and QacB of S. aureus and EmrB of E.coli. Bioinformatic analysis of M. tuberculosis 
genome has identified 16 open reading frames that encodes for putative drug pumps that 
belong to the MFS (De Rossi et al. 2006). In mycobacteria, most of the efflux pumps belong 
to this superfamily. 
In 1996, LfrA was discovered as the first multidrug efflux pump in M. smegmatis. LfrA 
belongs to MFS class, and is responsible for the intrinsic resistance to fluoroquinolones and 
tetracycline. The deletion of lfrA gene in different studies results in the increased 
susceptibility to a number of antimicrobials such as fluoroquinlones, ethidium bromide and 
acriflavine (Li et al. 2004). Several drug efflux pumps have subsequently been identified in 
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other mycobacteria and implicated in the mechanisms of drug resistance (Table 2.2) (Li et al. 
2004). 
o Multidrug and toxic compound extrusion (MATE) family 
The MATE transporters have been originally described in Vibrio parahaemolyticus (NorM), 
Vibrio cholera (VcrM; VcmA), E.coli (YdhE), Pseudomonas aeruginosa (PmpM), and 
Clostridium difficile (CdeA) (Omote et al. 2006). Most MATE transporters consist of 400 – 
550 residues with 12 transmembrane helices and they confer resistance to multiple toxic 
cationic agents, such as ethidium bromide, berberine, acriflavine and norfloxacin, using 
sodium ion gradient force across the plasma membrane. The use of sodium motive force as 
the driving force for drug extrusion to distinguish these efflux pumps to other secondary 
transporter families (Piddock 2006). 
o Small multidrug resistance (SMR) family 
The smallest efflux pumps belong to the SMR family. These transporter proteins have 
typically 100-120 amino acids and contain four membrane-spanning helices. SMR family 
pumps confer resistance to various compounds such as methyl viologen, benzalkonium, 
ethidium bromide, acriflavine, cetylpyridinium and proflavin. One of these pumps, EmrE, 
was cloned from E. coli and confers resistance to ethidium bromide and methyl viologen 
(Poulsen et al. 2011). The Mmr protein from M. tuberculosis was recently discovered, it 
confers resistance to ethidium bromide, acriflavine and methyl viologen. The purified Mmr 
protein had also demonstrated to function as a proton/drug antiporter in vitro (Nikaido 
2009). 
o Resistance nodulation division (RND) family 
The RND transporters are proteins with 12 transmembrane domains and include a number 
of multi-drug efflux proteins. Most RND transporters have been studied in Gram-negative 
bacteria and confer resistance to antibiotics in these microorganisms. The most studied 
examples of the RND transporters are the AcrAB-Tolc of E. coli and MexABOprM of 
Pseudomonas aeruginosa that catalyse the efflux of a number of antimicrobial agents 
(Piddock 2006; Poole 2007). 
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In mycobacteria, the identified drug efflux pumps are located in the cytoplasmic membrane. 
The genome of M. tuberculosis contains 13 genes that encode RND proteins designated 
MmpL (Mycobacterial membrane protein Large) (Domenech et al. 2005). The MmpL 
proteins are similar to each other in both sequence and structure; they each comprise 950 
amino acids residues and predicted to contain 12 membrane-spanning helices (De Rossi et 
al. 2006). 
1.5.5 Efflux pump inhibitors and their potential in TB treatment. 
Efflux pump inhibitors (EPIs) are a group of compounds that play a role in increasing the 
activity of antibiotics by limiting the function of efflux pumps. EPIs have the potential to 
contribute as antimicrobial agents in the treatment of TB, specifically in treating drug 
resistant TB (Dutta et al. 2010). 
Previous studies have demonstrated that EPIs such as thioridazine, carbonyl cyanide m-
chlorophenylhydrazone (CCCP), chlorpromazine, reserpine and verapamil have an inhibition 
effect against efflux pumps in mycobacteria (Paixão et al. 2009; Jin et al. 2010; Rodrigues et 
al. 2013).The combination of these EPIs with anti-TB drugs in vitro were shown to decrease 
the level of TB drug resistance in Mtb (Louw et al. 2009; Dutta et al. 2010). In mice infected 
with MDR strains, verapamil was able to restore susceptibility of the strains to first-line 
drugs (Louw et al. 2009). Another study has reported that a decrease in MIC and an increase 
in intracellular accumulation of ciprofloxacin in ciprofloxacin-susceptible and resistant 
strains of Mtb were related to the presence of reserpine (Huang et al. 2013). 
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Table 1.2: Mtb and Msmeg efflux pumps associated with drug resistance 
Mycobacteria Efflux pump Gene Family Inhibitor Drug resistance References 
Mtb  EfpA  efpA  MFS - INH (De Rossi et 
al. 2006) 
Mtb MmpL7 mmpL7 RND Reserpine 
CCCP 
INH (Sarathy et 
al. 2012) 






FQ (Pasca et al. 
2004) 




Doxorubicin (Louw et al. 
2009) 







Msmeg LfrA lfrA MFS CCCP FQ 
Doxorubicin 
(Li et al. 
2004) 
Mtb Mmr Rv3065 SMR CCCP Erythromycin (Rodrigues 
et al. 2013) 
Msmeg Tet(V) tet(V) MFS CCCP Tetracycline (De Rossi et 
al. 2006) 







1.6 New anti-tuberculosis drug candidates 
A number of compounds have been screened for TB drug development and many of these 
are already being tested in different phases of clinical trials. New anti-TB drugs should either 
reduce the length of TB treatment or minimise the doses administered under DOTS or be 
effective against MDR/XDR-TB or be able to respond in TB/HIV co-infection treatment. 
In line with these requirements, new anti-TB drugs should have divergent mechanisms of 
action by binding to targets that differ from those of old anti-TB drugs (Kremer and Besra 
2002). For some of these new drugs the mechanisms of resistance have already been 
described before entering into clinical trials (Rivers and Mancera 2008; Silva and Palomino 
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2011). Table 1.3 details the most promising new anti-TB drugs already in clinical trials and 
their targets. 
Table 1.3: New anti-TB drugs and their targets 
Drug Mode of action  Target Gene  References 
TMC207 
(diarylquinoline) 
Inhibition of ATP 
synthesis 
ATP synthase atpE  (Diacon et al. 




Inhibition of protein 
and cell wall lipids 
syntheses. 












Inhibition of mycolic 
acid and cell wall lipid 
syntheses 
Nitro reductase Rv3547  (Matsumoto et al. 
2006) 
SQ109 (diamine) Inhibition of cell wall 
synthesis 
MmpL3 mmpL3 (Tahlan et al. 
2012) 
Linezolid Inhibition of protein 
biosynthesis 
50S ribosomal subunit rplC (Livermore 2003; 
Escribano et al. 
2007) 
AZD5847 Inhibition of protein 
biosynthesis 
50S ribosomal subunit rrl; rplC (Balasubramanian 









Rv3790 (Makarov et al. 
2009) 
 
1.7 SQ109 as potential anti-TB candidate 
SQ109 (1, 2-ethylenediamine) is one of the most promising new anti-TB drugs. This 
compound is an analogue of EMB, and is currently being evaluated against Mtb in clinical 
trials (Sacksteder et al. 2012). SQ109 was chosen as a new anti-TB candidate, after the 
synthesis and screening of 63,238 compounds from a chemical library of 1, 2-
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ethylenediamine pharmacophores of EMB and entered pharmacological and toxicological 
tests in rats, dogs and monkeys before beginning its clinical phases (Sacksteder et al. 2012).  
SQ109 has shown activity in vitro and in vivo against both susceptible and resistant Mtb 
strains (Protopopova et al. 2005) and demonstrated synergy with current first-line drugs, RIF 
and INH, and an additive effect with streptomycin (Onajole et al. 2010; Sacksteder et al. 
2012). 
 
   
    Figure 1 1: Chemical structure of SQ109 
1.7.1 Mechanism of action of SQ109 
SQ109 is proposed to function by interfering with the assembly of mycolic acids into the cell 
wall of Mtb resulting in accumulation of trehalose monomycolate (TMM), which is the 
precursor of the trehalose dimycolate (TDM) (Tahlan et al. 2012). Kapil Tahlan et al. were 
unable to generate spontaneous SQ109-resistant mutants in Mtb, but they observed that 
mutants resistant to SQ109 analogues were also cross-resistant to SQ109. Whole-genome 
sequencing showed mutations in mmpL3 gene, which encodes a transporter of TMM, this 
implies that MmpL3 is the targets of SQ109 (Tahlan et al. 2012). Deletion of the homologue 
of MmpL3 in Msmeg, msmeg_0250 resulted in the intracellular accumulation of TMM, 
confirming its role in cell wall synthesis (Varela et al. 2012). 
MmpL3 is one of the MmpL proteins belonging to the resistance, nodulation, and cell 
division (RND) protein family. The RND proteins are a family of multidrug resistance pumps, 
specialised in transporting different molecules across the cell wall including drugs, fatty 
acids aliphatic and aromatics solvents (Domenech et al. 2005) as described in 2.5.3.2. MmpL 
proteins are present in both slow and fast growing mycobacteria and each protein 
transports specific molecules. For example in Mtb, MmpL7 is responsible for transporting 
phthiocero dimycocerostate (PDIM), while MmpL8 is required in sulfolipid 1 synthesis by 
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carrying a precursor of this substance (Pasca et al. 2005; Varela et al. 2012). A recent study 
reported that SQ109 is able to dissolve the transmembrane electrochemical proton 
gradient, suggesting that SQ109 acts on other essential processes in the cell beyond TMM 
transportation process (Li et al. 2014). 
1.7.2 Efflux as a mechanism of synergy for SQ109 
Several studies have demonstrated in vitro synergistic effect between the new anti-TB drug 
SQ109 and the front-line anti-TB drugs (Chen 2006; Onajole et al. 2010). In the case of RIF, 
the synergistic interaction occurs in both directions, i.e. SQ109 increases the activity of RIF 
and vice versa. A decrease in the MIC for RIF was observed in the presence of SQ109 in RIF 
resistant Mtb strains (Chen 2006). The mechanism of synergy between SQ109 and RIF and 
INH is not currently understood. Given that SQ109-resistant mutants were found to harbour 
mutations in the mmpL3 gene, which encodes a transporter, it is possible that SQ109 may 
exert its synergistic effect by modulating the transport of RIF and INH across the 
mycobacterial cell envelope. 
Hypothesis: SQ109 exerts its synergistic effect with RIF and INH by inhibiting drug efflux and 
increasing the intracellular drug concentration in mycobacterial cells. 
Aims: This study aimed to determine the influence of SQ109 exposure on efflux in Msmeg 
and to investigate the mechanism of synergy of SQ109 with RIF and INH in Msmeg by 
generating SQ109-resistant mutants. 
Objectives:  
1. To determine the influence of SQ109 on accumulation and efflux of EtBr in Msmeg 
using a semi-automated fluorometric assay. 
2. To determine the influence of SQ109 on rifampicin accumulation and efflux in 
Msmeg using a mass-spectrometry-based assay. 
3. To generate SQ109-resistant mutants of Msmeg and determine the susceptibility of 
these mutants to SQ109, rifampicin and isoniazid. 
4. To investigate the drug-drug interactions between SQ109 and rifampicin or isoniazid 
in SQ109-resistant mutants. 
5. To identify the chromosomal mutation responsible for SQ109 resistance in Msmeg. 
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Msmeg is a non-pathogenic, fast-growing organism which is closely related to Mtb and 
shares more than 2000 homologues with Mtb including the same unusual cell wall structure. 
Both, Msmeg and Mtb show synergy with rifampicin and isoniazid, therefore we 
hypothesize that the mechanism is the same in both species. The EtBr efflux assay used in 
this study could not be performed in the BSL3 facility since the RotoGeneTM 6000 instrument 
required is not present in this facility. The assay could therefore only be performed in a BSL2 
laboratory. Msmeg was therefore used as a model organism in this study to investigate 
efflux as the mechanism of synergy of SQ109 with rifampicin and isoniazid in mycobacteria 
(Kang et al. 2008; Chao et al. 2013).  
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Chapter 2 
Materials and methods 
 
2.1 Bacterial strains, media and growth conditions 
Mycobacterium smegmatis mc2155 (Msmeg) was obtained from the Division of Molecular 
Biology and Human Genetics at Stellenbosch University (South Africa) and maintained as a 
frozen glycerol stock at –80oC for all experiments done in this project. Liquid cultures of 
Msmeg were grown in Middlebrook 7H9 medium (Becton Dickinson, Franklin Lakes, NJ, 
USA) supplemented with 2% glucose, 0.85% sodium chloride (NaCl) and 0.05% Tween 80 
(7H9 glucose-salt), and incubated at 37oC in a shaking incubator at 200 rpm. Solid cultures 
were maintained on 7H10 agar (Becton Dickinson) supplemented with 2% glucose, 0.85% 
sodium chloride (NaCl) and incubated at 37oC.  
Growth curves were performed by inoculating a 1 ml glycerol stock into 50 ml 7H9 glucose-
salt and incubated for 12 hours. This starter culture was then used to inoculate a volume of 
0.5 ml in liquid culture, which was subsequently incubated for 27 hours, and the growth 
monitored by transferring 1 ml of each culture into a cuvette and measuring the OD600nm at 
intervals of 3 hours. Cultures with OD600nm readings above 1 were diluted appropriately. 
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2.2 Compounds 
The compounds listed in table 2.1 were used in this project. 
Table 2.1: Compounds used  
Compounds Supplier Stock solution concentration, 
diluent and storage conditions 
Ethidium bromide (EtBr) Sigma-Aldrich, 
Johannesburg, South Africa 
10 mg/ml in distilled sterile 
water, stored at room 
temperature. 
Rifampicin (RIF) Sigma-Aldrich, 
Johannesburg, South Africa 
4 mg/ml in DMSO/water mixture 
(9:1) stored as frozen aliquots at  
-80oC. 
Isoniazid (INH) Sigma-Aldrich, 
Johannesburg, South Africa 
10 mg/ml in distilled sterile 
water. Stored as frozen aliquots 
at -80oC. 
SQ109 Sequella, Rockville, MD, 
USA 
10 mg/ml in distilled sterile 
water. Stored as frozen aliquots 
at-80oC. 
Verapamil (VP) Sigma-Aldrich, 
Johannesburg, South Africa 
0.4 mg/ml in distilled sterile 
water. Stored as frozen aliquots 
at -80oC. 
 
All working solutions were prepared from defrosted aliquots in distilled water to obtain the 
required working concentration. 
2.3 Determination of the Minimum Inhibitory Concentrations 
The minimum inhibitory concentration (MIC) of a compound is defined as the lowest 
concentration of the compound that inhibits the visible growth of a microorganism. MICs of 
all compounds were determined by broth micro-dilution method in 96-well micro titre 
plates (Greiner bio one, Frickenhausen, Germany) and after incubation period, results were 
visually read and recorded (Jenkins and Schuetz 2012). 
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2.3.1 Broth micro dilution method 
The broth micro dilution method allows the testing of a range of compound concentrations 
on a single 96-well micro titre plate (Greiner bio one, Frickenhausen, Germany) for MIC 
determination (Andrews 2001; Luber et al. 2003; Wiegand et al. 2008). Briefly, a 20 ml 
starter culture was inoculated using 1 ml of an Msmeg glycerol stock and grown overnight at 
37oC in the shaking incubator at 200 rpm to an OD600nm of 0.8. A volume of 1 ml was then 
sub-cultured into 20 ml of 7H9 glucose-salt and grown to an OD600nm of 0.8. The culture was 
then diluted 1:100 in 7H9 broth containing glucose-salt. 
A 96-well plate with 12 rows containing 8 wells each was prepared by adding 50 µl of 7H9 
glucose-salt to each well in Row 2 to 12. Row 1 was loaded with 100 µl of each drug, diluent 






100 µl  
compound A 
at 4 X maximum 
concentration 
100 µl  
Compound A 
at 4 X maximum 
concentration 
100 µl  
compound B 
at 4 X maximum 
concentration 
100 µl  
compound B 








A 1 in 2 serial dilution was performed by transferring 50 µl of the solutions from Row 1 to 
Row 2 using a multichannel pipette. The solutions from Row 2 were mixed and then 50 µl 
were transferred to Row 3, and so on, until Row 12 was reached. The last 50 µl were 
discarded to bring the volume down to 50 µl. Finally, 50 µl of diluted Msmeg culture was 
added to each well from Row 2 to 12. The micro titre plate was sealed with sealing film, 
placed back into the original plastic bag and incubated at 37oC for 3 to 4 days. After the 
incubation period, wells which had visible growth were scored and the MIC was defined as 
the concentration range between the highest concentration of the compound at which 
growth was observed and the lowest concentration that inhibited visible growth.  
2.3.2 MIC on solid media 
The MIC of SQ109 for Msmeg was determined in duplicate on 7H10 agar (Becton Dickinson) 
supplemented with 2% glucose and 0.85% sodium chloride (NaCl). Middlebrook 7H10 agar 
quadrant plates (8 divisions) were prepared to contain the following concentrations of 
SQ109: 5.0, 10, 15, 25 and 50 µg/ml. Msmeg was cultured overnight at 37oC in the shaking 
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incubator at 200 rpm to an OD600nm of 0.8. A 10-fold serial dilution of the culture from 10-1 
up to 10-8 was prepared and a volume of 10 µl of each dilution was spread onto the 
corresponding dilution quadrant of 7H10 agar plates containing different drug 
concentrations. The plates were incubated at 37oC for 3 to 4 days (Heifets and Lindholm-
Levy 1989). The concentration that resulted in the complete inhibition of mycobacterial 
growth after incubation was recorded as the MIC of the drug. Plates with no drug were used 
as controls. 
2.4 Semi-automated fluorometric accumulation and efflux assays 
Mycobacteria are resistant to most of the commonly used antimicrobial agents due to the 
structure of their cell wall which is rich in lipid composition and plays a role of a barrier to 
noxious compounds and contributes to the slow drug uptake (Rodrigues et al. 2011). 
Active efflux pump systems extrude noxious compounds and antibiotics from the cell 
reducing their intracellular concentration (Rodrigues et al. 2011), therefore reduced 
permeability of mycobacterial cell wall and active efflux systems are two main mechanisms 
that contribute to mycobacterial intrinsic resistance to a number of antibiotics (Louw et al. 
2009). 
Several methods have been used to study the balance between entry and extrusion of a 
given compound. These include the measurement of radiolabelled or metal-labelled 
substrate. The semi-automated fluorometric method has been developed using a real-time 
thermocycler to assess accumulation and efflux by measuring the fluorescence of EtBr 
(Paixão et al. 2009; Machado et al. 2012). 
EtBr is a membrane penetrating dye which has a low fluorescence outside the cell. Once 
EtBr is inside the cell its fluorescence increases because it binds to the DNA. In a semi-
automated assay the fluorescence of EtBr is read and quantified using the Rotor-
GeneTM 6000 (Corbett Research, Sidney, Australia) which allows multiple samples to be 
monitored simultaneously in a temperature-controlled environment. 
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2.4.1 Ethidium bromide accumulation assay 
Msmeg was cultured in 20 ml of 7H9 glucose-salt until it reached a mid-log phase 
corresponding to an OD600nm of 0.8. The culture was then centrifuged at 13,000 rpm for 3 
minutes. After discarding the supernatant, the pellet was washed twice with an equal 
volume of phosphate buffered saline (PBS), re-suspended in PBS, and adjusted to an OD600nm 
of 0.4. The accumulation assays were performed in 200 µl PCR micro tubes with 100 µl as a 
final volume of solutions. In order to determine the optimum EtBr concentration for the 
assay, 10 µl of EtBr solutions with different concentrations were added to 90 µl of 
mycobacterial culture. The final concentrations of EtBr in each mixture were as follows: 
0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 µg/ml. Micro tubes were placed into a 36-well rotor in the 
Rotor-GeneTM 6000 and the fluorescence of EtBr was determined each minute for the first 
60 minutes at 25oC.  
To determine the inhibitory effect of SQ109 on EtBr accumulation in Msmeg, mycobacterial 
cells were prepared as described above. After adjusting the OD to 0.4, EtBr was added into a 
cell suspension to a final concentration of 0.5 µg/ml (Concentration that resulted to a 
minimal accumulation of EtBr). Volumes of 95 µl were transferred into micro tubes and 5 µl 
of verapamil or SQ109 at their half MICs (100 µg/ml and 1.0 µg/ml respectively) or water 
(micro tubes served as controls) were added (Jin et al. 2010; Rodrigues et al. 2011). 
Verapamil is a known efflux inhibitor and therefore served as a positive control. Micro tubes 
were placed into a 36-well rotor and the fluorescence of EtBr was acquired as described 
above. Every experiment was performed in triplicate. 
2.4.2 Ethidium bromide efflux assay 
Mycobacterial cells were loaded with EtBr by incubating a cell suspension prepared as 
described in 3.4.1 with 3.125 µg/ml EtBr and 100 µg/ml verapamil at 25oC (concentrations 
correspond to half of the MIC of both compounds) for 60 minutes to ensure a maximum 
accumulation of EtBr without compromising the cellular viability (Paixão et al. 2009; 
Rodrigues et al. 2011). 
The EtBr loaded cells were centrifuged at 13,000 rpm for 3 minutes and the pellet was 
washed with PBS. The washed cells were then re-suspended in EtBr-free PBS and the 
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OD600nm was adjusted to 0.4. Volumes of 95 µl were transferred into micro tubes and 5 µl of 
verapamil, SQ109 or water was added as required. The efflux of EtBr was determined by its 
fluorescence as described 3.4.1 (Rodrigues et al. 2011). 
2.5 Rifampicin accumulation in Msmeg 
RIF is one of the first anti-TB drugs and previous studies have suggested that efflux of RIF 
plays a role in determining the level of resistance of mycobacteria to this drug. We have 
utilised a mass spectrometry-based assay to determine the intracellular concentration of RIF 
in the presence of SQ109 and a known efflux pump inhibitor, verapamil.  
2.5.1 Rifampicin accumulation assay 
An Msmeg starter culture was grown as described in 3.1 and 5 ml of this was used to 
inoculate 150 ml of 7H9 broth. This subculture was grown to an OD600nm of 0.8 and the 
dividing mycobacteria were harvested by centrifugation for 10 minutes at 3,200 x g at room 
temperature. The supernatant was discarded, the pellet re-suspended in 10 ml PBS and the 
culture adjusted to an OD600nm of 4.0.  
The uptake of RIF was performed by exposing mycobacteria to RIF with a concentration of 
8.23 µg/ml for 20 minutes. Three aliquots of 500 µl each were removed after 0, 5, 10 and 20 
minutes and loaded onto a 0.22 µm micro centrifugal filter (Millipore Millex-GV 
polyvinylidene difluoride PVDF membrane; ultra-free MC Dura 0.22/µm pore size, Merck, 
Darmstadt, Germany) The samples were centrifuged at 4oC for 1 minute at 13,000 x g and 
the flow-through was discarded. The cells retained on the membrane were re-suspended in 
500 µl ice-cold PBS, spun down again (13,000 x g for 1 minute at 4oC) to wash the cells. The 
pellet was re-suspended in 500 µl sterile water. The washed mycobacteria were then 
disrupted by probe sonication three times for 15 seconds at 4oC (amplitude: 20; energy: 30 
J). The lysates were cleared by centrifugation at 4oC for 5 minutes at 13,000 x g and 4oC then 
filtered through a sterile membrane as above. Finally, 130 µl of methanol and 65 µl of 
acetonitrile were added to the flow-through and the samples were stored at -20oC until 
analysis. 
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To investigate the effect of verapamil or SQ109 on RIF accumulation, cells were pre-
incubated with either compound at a concentration of half their MIC for 3 minutes prior to 
the addition of RIF. 
2.5.2 Quantification of rifampicin concentration in cell lysates using LC-MS method 
Samples containing RIF were sent to the central analytical facilities (Mass Spectrometry unit) 
at Stellenbosch University for RIF concentration determination by liquid chromatography-
tandem mass spectrometry. The analysis was performed with a Thermo Scientific Easy-nLC II 
system connected to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, 
Germany). 
2.5.3 RCDC protein determination assay 
The protein content of the lysates was determined in order to normalise the RIF 
concentration obtained to total protein. This was determined by RCDC (Reducing Agent and 
Detergent Compatible) method as follows: 
A protein standard curve was prepared from a 1.5 mg/ml Bovine Serum Albumin (BSA) stock 
solution (Bio-Rad Laboratories, Hercules, CA) as indicated in Table 2.2.  
Table 2.2: BSA standard curve preparation 
BSA concentration (mg/ml) 1.5 mg/ml BSA stock (µl) Sterile water (µl) 
0 0 25 
0.1 1.67 23.33 
0.2 3.33 21.67 
0.5 8.33 16.67 
1.0 16.67 8.33 
1.5 25 0 
 
The determination was conducted according to the instructions of the manufacturer of the 
protein assay kit (Bio-Rad Laboratories, Hercules, CA) with each lysate and BSA standard 
curve sample. Briefly, aliquots of 25 µl from each sample were transferred into 1.5 ml 
Eppendorf tubes and 125 µl of buffer R1 was added. All specimens were mixed well by 
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vortexing for 20 seconds, a volume of 125 µl buffer R2 was added and each sample vortexed 
again for 20 seconds. All samples were centrifuged for 5 minutes at 15,000 X g and 4°C, the 
supernatant removed and the pellets were left to dry for 5 minutes. After this, a mixture of 
buffer A and buffer S (125 µl of A + 2.5 µl of S per sample) was prepared and 127 µl were 
added to each sample. A volume of 1 ml of reagent B was added to each tube and all were 
left at room temperature for 15 minutes. The mixture was then transferred into a plastic 
cuvette and the OD595nm was determined using a spectrophotometer. A protein standard 
curve was plotted using Excel software and used to determine the protein concentration in 
each sample. When appropriate, dilutions of the samples were made. 
2.6 Isolation of spontaneous SQ109-resistant mutants in Msmeg 
Genetic mutations confer resistance to many antibiotics in bacteria. Mutations may occur 
spontaneously in the chromosomal genes or through gene transfer of plasmids between 
bacteria by either conjugation, transduction or transfection via bacteriophages (Pope et al. 
2008). In vitro, the selection of spontaneous mutations that result in resistance to a drug 
can be done by culturing bacterial strains in the presence of a concentration above the MIC 
for that drug (Morlock et al. 2000; Boshoff et al. 2003). The mutation rate, which is the 
chance of a mutation to occur per cell generation, and the mutation frequency, which is 
defined as the proportion of mutants per culture, can be determined experimentally 
(Morlock et al. 2000; Wang et al. 2001; Pope et al. 2008). 
SQ109 resistant mutants were generated by culturing Msmeg in 20 ml of 7H9 glucose-salt at 
37oC overnight to an OD600nm of 0.8. The culture was diluted and inoculated into 50 ml of 
7H9 broth corresponding to approximately 106 CFU/ml. Aliquots of 5 ml were dispensed into 
10 culture tubes and the tubes were incubated at 37oC for 3 days in a shaking incubator at 
200 rpm (Morlock et al. 2000; Boshoff et al. 2003). The cells were pelleted by centrifugation 
at 1,811 x g for 10 minutes at room temperature and the supernatant was discarded. The 
bacterial pellet was re-suspended in 1 ml water with 0.5% Tween 80, centrifuged again and 
the supernatant aspirated, leaving a small amount of liquid. The pellet was then re-
suspended, and the cultures were spread in duplicate onto Middlebrook 7H10 solid media 
with glucose-salt supplement and SQ109 at either of the following concentrations: 10, 25 or 
50 µg/ml. One of the 10 tubes was used to determine the CFU/ml by plating serial dilutions 
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(10-5 – 10-10) of the culture on 7H10 glucose-salt without drug. All plates were incubated for 
10 days at 37oC. 
2.6.1 PCR and agarose gel electrophoresis 
The extraction of the DNA template from Msmeg wild-type and mutants for PCR was started 
by heating the cells in order to disrupt the cell envelope. A volume of 300 µl from Msmeg 
wild-type or mutant culture was boiled at 95oC in a heating block for 10 minutes. After 
cooling to room temperature, the samples were centrifuged at 13,000 rpm for 5 minutes 
and the supernatant was immediately processed or kept in the freezer at -20oC as DNA 
template. 
To amplify the MSMEG_0250 gene (3042 bp), four sets of primers were designed using 
primer3 program (primer3.ut.ee) version 4.0 as shown in Table 2.3. The PCR reaction 
contained 10 x PCR Buffer with 2 mM MgCl2, 1 mM 5 X GC-RICH solution, 200 µM of each 
dNTP, 0.5 µM of each primer, 2 U/µl of FastStart Taq DNA polymerase and 1 µl DNA 
template and nuclease-free water to a final volume of 50 µl. The PCR amplification was 
carried out as follows: 2 minutes initial denaturation at 95oC, 35 cycles with 30 seconds 
denaturation at 95oC, 30 seconds annealing at 55oC and 1.5 minutes elongation at 72oC, 
followed by 7 minutes of final elongation at 72oC. The PCR products were separated on a 1% 
agarose gel using the TBE buffer system (0.089 M Tris base, 0.089 M Boric acid and 2 mM 
EDTA as final concentration in the 1 x TBE buffer with a pH of 8) with 5 µl of Ethidium 
bromide (final concentration of 0.5 µg/ml). A volume of 10 µl of 6 x DNA loading buffer 
(Thermo scientific) was added to each 50 µl PCR product and 10 µl of the sample was then 
loaded onto the gel. The DNA electrophoresis was performed at 104 volts for 1 hour in 1 X 
TBE buffer. A 1 kb DNA marker (Thermo scientific) was used as comparison for the sizes of 
the DNA fragments and the bands were visualised with the Gel Doc Imaging System (Bio-Rad 
Laboratories, Johannesburg, South Africa). 
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Table 2.3: Primers used for MSMEG_0250 gene amplification 
  Primer name Sequence 
  Fo1 5’- GGT CGG ACC GTG TAC CAG - 3’ 
  Re1 5’- GTG CAC GGG GGT GAA CTC - 3’ 
  Fo2 5’- ATC GGC GAG GAC CAG AAG - 3’ 
  Re2 5’- GGC AGG TAT TTC TCG CTG A - 3’ 
  Fo3 5’- GGC GGT ATC AGC GAG AAA TA - 3’ 
  Re3 5’- AGA CCC AGC TTC TCC TGC AC - 3’ 
  Fo4 5’- GTG CAG GAG AAG CTG GGT CT - 3’ 
  Re4 5’- GCT TGG TCT CCG GAT CCT C - 3’ 
 
2.6 2. Sanger DNA sequencing 
Sanger’s method is a DNA sequencing procedure developed by Frederick Sanger and 
colleagues in 1977 (Sanger and Coulson 1975). The method is based on the addition of 
chain-terminating dideoxynucleotides (ddNTP’s) to the normal nucleotides (NTP’s) by DNA 
polymerase during replication of DNA (Sanger and Coulson 1975). Dideoxynucleotides differ 
to the normal nucleotides by the presence of a hydrogen group on the 3’ carbon instead of a 
hydroxyl group (OH) (Murphy et al. 2005). The incorporation of these modified nucleotides 
into the sequence prevents the integration of normal nucleotides because the 
phosphodiester bond cannot be established between the dideoxynucleotide and the next 
nucleotide. This results in the termination of the DNA chain (Murphy et al. 2005). For each 
piece of DNA to be sequenced, four sequencing reactions are required. Each reaction 
contains all four dNTPs and one of the four modified nucleotides (ddATP, ddGTP, ddCTP and 
ddTTP). Following amplification, each of the four reactions is run in a separate lane on a 
polyacrylamide gel in order to visualise the different sized DNA bands, each terminated at a 
different position in the sequence where the specific dideoxynucleotide has been 
incorporated (Murphy et al. 2005; Morozova and Marra 2008). PCR products which 
corresponded to the correct amplicon size were sent to the central analytical facilities (DNA 
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sequencing unit) at Stellenbosch University for Sanger DNA sequencing. Data were analysed 
using the DNA sequence analysis software, sequencer version 5.1. 
2.7 Checkerboard drug-interaction assays  
Testing of interactions between drugs is an important step in the development of new anti-
TB drugs since any new drug would have to be included into the existing regimen. The 
micro-dilution checkerboard method is one of the methods used in the laboratory for drug 
interaction assessment. The method uses 96-well micro titre plates containing serial 
dilutions of drug concentrations alone and in combination (Jenkins and Schuetz 2012). The 
effect occurring during drug interactions may be synergistic, additive, indifferent or 
antagonistic (Sopirala et al. 2010; Tan et al. 2011; Jenkins and Schuetz 2012) and this is 
determined by calculating the fractional inhibitory concentration index (FICI) as follows: 
FICI = FIC of drug A + FIC of drug B 
FIC of drug A =  FIC of drug B =  
The FICI is interpreted as follows: 
FICI  : defined as synergy  FICI  : defined as additivity 
FICI  : defined as indifference FICI  : defined as antagonism 
Experiments on drug interactions were determined by checkerboard titration and 
performed using the broth micro dilution method as described in 3.3.1. For this, each well of 
the 96-well plate contained 50 µl of solution with combinations of drugs. The dilution of the 
first drug was done from Column 1 to Column 11, skipping Column 2 while the second drug 
was diluted from Row A to Row H, skipping row B of the 96-well plate. Row B was used for 
the MIC determination of the first drug alone and Column 2 for the MIC of the second drug 
alone. Column 12 was inoculated with media and fresh culture only, and served as a drug 
free control, 50 µl of freshly grown and diluted culture was added to each well containing 
drugs in different concentrations. Plates were incubated and analysed as described above 
for broth micro dilution assay. 
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The table 2.4 represents the design of a 96 well plate that was used for drug interaction 
determination. 
Table 2.4: 96 well plate design used for drug interaction assays 
                                   Drug B at 4 X max conc. Without diluted culture  
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2.8 Whole genome sequencing of Msmeg SQ109-resistant mutants 
Next Generation Sequencing (NGS) methods have been developed to sequence an entire 
genome from a single sample in a short time, and this technology is used for sequencing 
large genomes (human genomes) or small genomes such as viral and bacterial genomes 
(Grada and Weinbrecht 2013). Several potential applications can be run by NGS 
technologies such as whole genome sequencing (WGS) and whole exon sequencing (WES) 
for mutation detection, transcriptome sequencing for gene expression determination, 
targeted sequencing for mutation validation and epigenetic markers confirmation for 
disease diagnosis (Liu et al. 2012; Xuan et al. 2013). 
Different NGS platforms have emerged with ultra-high-throughput and low-cost effective 
interests. The Illumina sequencing system is one of the most commonly used NGS platform 
and can process 35-bp reads and produce about 1 Giga base (Gb) of good quality sequence 
per run within 2 to 3 days. The Illumina technology uses the sequencing by synthesis (SBS) 
method (Ansorge 2009). 
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2.8.1 Phenol-chloroform isoamyl alcohol (PCI) DNA extraction 
To detect the mutations in the whole genomic DNA of Msmeg SQ109-resistant mutants, the 
DNA was extracted using the Phenol-Chloroform Isoamyl Alcohol (PCI) method. Briefly, 
colonies were grown in liquid medium as described in 3.1 and 100 µl of each culture was 
plated out onto 7H10 agar (Becton Dickinson) supplemented with glucose-salt. The plates 
were incubated for 5 days at 37oC and then placed in an oven for one hour at 80oC to 
inactivate the mycobacteria. The confluent growth was harvested using a sterile loop and 
transferred into a 50 ml Falcon tube containing 6 ml of DNA extraction buffer (pH 7.4) and 
glass beads (4 mm, filled up to 3 ml in Falcon tube). The bacteria were vortexed for 2 
minutes, 100 µg/ml of lysozyme and 10 µg/ml of RNAse A were added and the mixtures 
incubated for 2 hours at 37oC. Finally, 600 µl of proteinase K buffer and 300 µl of proteinase 
K enzyme were added to the tubes which were incubated for 16 hours at 45oC. 
A volume of 5 ml of Phenol-Chloroform Isoamyl Alcohol was added to the tubes, which were 
then incubated for 2 hours at room temperature, with inversion every 30 minutes. The 
tubes were centrifuged at 1,811 x g for 20 minutes at room temperature and three separate 
layers were obtained, namely an aqueous top phase containing DNA, an interphase and an 
organic phase. The top phases were carefully removed and transferred into new 50 ml 
Falcon tubes each containing 5 ml of Chloroform Isoamyl Alcohol and a second 
centrifugation step was performed at 1,811 x g for 20 minutes at room temperature.  
The supernatants with DNA were carefully removed and transferred into new 50 ml Falcon 
tubes containing 600 µl of sodium acetate. The tubes were gently inverted for 5 minutes 
followed by an addition of 7 ml ice-cold isopropanol.  
The tubes were again gently inverted and the DNA was fished using glass rods. The glass 
rods were placed for 10 minutes in 1.5 ml Eppendorf tubes with 1 ml 70% ethanol, then 
transferred to a clean Eppendorf and allowed to air dry for 2 to 3 hours at room 
temperature. A volume of 300 µl of TE buffer was added to each tube with a glass rod to 
dissolve the DNA. All samples were stored at -20oC prior to whole genome sequencing.  
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2.8.2 Whole genome sequencing 
DNA samples were sent to the University of the Western Cape for whole genome 
sequencing. The analysis of WGS data was performed by Dr M de Vos as follows: 
The analysis pipeline includes the use of three different aligners (BWA, Novoalign and 
SMALT) to map the sequencing reads for each isolate to the reference Msmeg genome. The 
Genome Analysis ToolKit (GATK) was then used to identify variants (SNPs and Indels) from 
each aligner file for each sequenced isolate relative to the reference Msmeg genome. A 
variant was considered to be high confidence if it was identified in all three alignment files 
and only these were used for subsequent analysis. Due to the overall low coverage of the 
sequencing data, a variant was only considered for future analysis if it was covered by at 
least 10 reads. 
To recognise variants that were acquired in the mutant isolates, the high confidence 
variants identified for the wild type isolate were compared to the variants identified for 
each of the mutant isolates. The unique variants for each mutant isolate were manually 
inspected using GenomeView to ensure that the variant considered unique to one isolate 
was not present in the wild-type isolate. The read coverage of each variant was also used to 
classify each variant as fixed (the variant allele occurs in more than 80 % of the reads) or 
heterogeneous (the variant allele occurs in between 20-80 % of the reads). 
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3.1 Minimum inhibitory concentration determination 
The MICs of the following compounds against wild-type Msmeg were determined by broth 
micro dilution in 7H9: EtBr, verapamil, RIF, INH, SQ109 and values used in subsequent 
experiments (Andrews 2001; Paixão et al. 2009). Compounds were tested in the following 
ranges: 200 - 0.195 µg/ml (EtBr), 6,400 - 6.25 µg/ml (verapamil) and 64 - 0.0625 µg/ml for 
the three antibiotics. The MIC was defined as the median between the highest 
concentration of the compound at which growth was observed and the lowest 
concentration that inhibited visible growth. The MIC results of all compounds are shown in 
Table 3.1. 
Table 3.1: MICs of various compounds for Msmeg in liquid medium 
Compound Range (µg/ml) MIC (µg/ml) 
EtBr 200 – 0.195 6.25 - 12.5 
Verapamil 6400 – 6.25 200 - 400 
SQ109 64 – 0.0625 2.0 – 4.0 
RIF 64 – 0.0625 0.5 – 1.0 
INH 64 – 0.0625 4.0  - 8.0 
 
The MIC of SQ109 was also determined for Msmeg on solid media. 10 µg/ml was chosen as 
the MIC of SQ109 for Msmeg on solid medium. In comparison to liquid medium, the MIC of 
SQ109 was five times higher on agar than in broth. 
3.2 Assessment of the effect of SQ109 on EtBr accumulation in Msmeg 
The effect of SQ109 on efflux pump activity in Msmeg was assessed by monitoring the rate 
of accumulation or efflux of EtBr. In order to determine the optimum EtBr concentration for 
these assays, the level of accumulation of different concentrations of EtBr by Msmeg was 
Stellenbosch University  https://scholar.sun.ac.za
  31 
assessed (Figure 3.1). As expected, an increase in fluorescence was observed as the 
concentration of EtBr was increased in the assay.  
   

































Figure 3.1: Accumulation of EtBr by Msmeg at increasing concentrations. Mycobacterial cells were exposed to 
different concentrations of EtBr ranging from 0.125 to 4 µg/ml. The fluorescence of EtBr was monitored at 
25oC every minute for a period of 60 minutes.  
EtBr enters the cell by diffusion, but must be actively pumped out of the cell by efflux 
pumps. At 0.5 µg/ml, very little increase in fluorescence is observed, suggesting that the 
efflux pumps are able to pump out the EtBr before it is able to interact with DNA and 
proteins within the cells. As the EtBr concentration is increased however, the efflux pumps 
are not able to extrude the EtBr at a high enough rate and this allows EtBr to bind to 
intracellular components, causing an increase in fluorescence. An EtBr concentration of 
0.5 µg/ml was therefore selected for subsequent efflux experiments as the effect of a 
compound that inhibited efflux would be more easily detected using this concentration. 
Verapamil was previously demonstrated to inhibit efflux in mycobacteria and was therefore 
used as a positive control for this assay. Addition of verapamil to the efflux assay resulted in 
an increase in EtBr accumulation as previously reported (Figure 3.2). Performing the efflux 
assay in the presence of SQ109 appeared to inhibit EtBr efflux in some experiments, but this 
result was not reproducible (Fig 3.2 9 (c) and (d)).   
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Figure 3.2: Effect of verapamil and SQ109 on accumulation of EtBr by Msmeg. Mycobacterial cells were 
loaded with 0.5 µg/ml of EtBr in presence of verapamil or SQ109. The fluorescence was assessed at 25oC every 
minute for a period of 60 minutes. Results from 4 experiments (a), (b), (c) and (d) are shown. 
As an alternative for measuring the effect of SQ109 on efflux in Msmeg, an assay measuring 
the rate of efflux from cells pre-loaded with EtBr was performed. Once again, the rate of 
efflux was decrease in the presence of verapamil (Figure 3.3). The rate of efflux in the 
presence of SQ109 appeared to be marginally lower, however as with the previous assay, 
these results were not definitive because of the variation observed between the 
experiments. 
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Figure 3.3: Effect of verapamil and SQ109 on the efflux of EtBr in Msmeg. Mycobacterial cells were pre-
loaded with EtBr in the presence of verapamil for 60 minutes to reach the maximun accumulation. The 
fluorescence was assessed at 25oC every minute for a period of 60 minutes after the addition of verapamil or 
SQ109. Results from 4 experiments (a), (b), (c) and (d) are shown. 
Since the EtBr accumulation and efflux assays did not yield definitive results, an alternative 
assay to test the effect of SQ109 on RIF accumulation by quantifying the concentrations of 
RIF in cell lysates using liquid chromatography-tandem mass spectrometry was employed. 
3.3 Assessment of the effect of SQ109 on RIF accumulation in Msmeg 
Previous studies have demonstrated that RIF is extruded from mycobacteria by efflux 
pumps (Piddock et al. 2000; Poole 2007; Louw et al. 2009; Balganesh et al. 2012). In order to 
determine the effect of SQ109 on the accumulation of RIF in Msmeg cells, the intracellular 
RIF concentration of cells was measured by LC-MS/MS over time following the addition of 
RIF to a cell suspension (Figure 3.4). The addition of verapamil resulted in an increased RIF 
accumulation, while SQ109 appeared to have no significant influence on RIF accumulation. 
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Figure 3.4: RIF intracellular concentration measurements in Msmeg after 0, 5, 10 and 20 minutes of 
exposure. 
3.4 Evaluation of growth of wild-type and SQ109-resistant strains of Msmeg in liquid 
culture 
SQ109-resistant mutants of Msmeg were selected on plates containing 50 µg/ml of SQ109. 
Six SQ109-resistant mutants were selected for further characterisation. The growth of the 6 
mutants and the wild type parental strain was assessed in complete media over 72 hours 
(Figure 3.5). No difference in the growth kinetics between the wild type and the mutant 
strains were observed. 
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Figure 3.5: Growth curves of Msmeg SQ109-resistant mutants and wild-type 
This indicates that the acquisition of resistance to SQ109 does not reduce the fitness of 
Msmeg under the conditions tested (Figure 3.5). 
3.5 Minimum inhibition concentration determination for SQ109-resistant mutants 
The MICs of RIF, INH and SQ109 for each of the 6 mutants were determined by broth micro-
dilution (Table 3.2). The MICs of RIF and INH were increased 4-fold compared to wild-type 
while the MIC of SQ109 showed an increase of 20-fold. There was no difference in MICs 
between the mutants for RIF and INH, whereas the value for SQ109 of mutant 6 was 
between 40 – 50 µg/ml compared to the lower MIC 35-45 µg/ml (Table 3.1 and 3.2). 
Stellenbosch University  https://scholar.sun.ac.za
  38 
Table 3.2: MICs of RIF, INH and SQ109 for SQ109-resistant mutants of Msmeg 
Msmeg SQ109 
resistant- mutants 
Rifampicin (µg/ml) Isoniazid (µg/ml) SQ109 (µg/ml) 
Mutant 1 2.0 – 4.0 16 - 32 35 – 45  
Mutant 2 2.0 – 4.0 16 - 32 35 – 45 
Mutant 3 2.0 – 4.0 16 - 32 35 – 45 
Mutant 4 2.0 – 4.0 16 - 32 35 – 45 
Mutant 5 2.0 – 4.0 16 - 32 35 – 45 
Mutant 6 2.0 – 4.0 16 - 32 40 – 50 
 
3.6 Assessment of drug-interactions in wild type and SQ109-resistant mutants 
Previous studies have demonstrated that SQ109 and the first-line drugs RIF and INH act 
synergistically against Msmeg (Chen 2006; Reddy et al. 2010). The combined activity of 
SQ109 with either RIF or INH against wild-type and SQ109-resistant strains of Msmeg was 
therefore assessed. 
Table 3.3: Interaction between SQ109 and RIF against wild type strain of Msmeg 
32 16 8 4 2 1 0.5 0.25 0.125 0
4 - - - - - - - - - -
2 - - - - - - - - - -
1 - - - - - - - - - -
0.5 - - - - - - - - + +
0.25 - - - - - - - + + +
0.125 - - - - + + + + + +
0 - - - - + + + + + +
                                                                                                                 SQ109 (µg/ml)
RIF(µg/ml)
  +  indicates growth,     -  indicates no growth,     Shaded boxes indicate  synergy between two drugs  
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Table 3.4: Interaction between SQ109 and INH against wild type strain of Msmeg 
32 16 8 4 2 1 0.5 0.25 0.125 0
16 - - - - - - - - - -
8 - - - - - - - - - -
4 - - - - - - - - - +
2 - - - - - - - - + +
1 - - - - - - + + + +
0.5 - - - - + + + + + +
0 - - - - + + + + + +
                                                                                                                 SQ109 (µg/ml)
INH(µg/ml)
 +  indicates growth,   -  indicates no growth,      Shaded boxes indicate  synergy between two drugs  
Table 3.5: Interaction between SQ109 and RIF against SQ109-resistant strain of Msmeg 
65 60 55 50 45 40 35 30 25 20 0
16 - - - - - - - - - - -
8 - - - - - - - - - - -
4 - - - - - - - - - - -
2 - - - - - - - - + + +
1 - - - - - - - + + + +
0.5 - - - - - + + + + + +
0.25 - - - - - + + + + + +
0 - - - - - + + + + + +RIF(µg/ml)
  +  indicates growth,     -  indicates no growth,     Shaded boxes indicate  additivity between two drugs
                                                                                                                                                            SQ109 (µg/ml)
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Table 3.6: Interaction between SQ109 and INH against SQ109-resistant strain of Msmeg 
65 60 55 50 45 40 35 30 25 20 0
64 - - - - - - - - - - -
32 - - - - - - - - - - -
16 - - - - - - - - + + +
8 - - - - - - - - + + +
4 - - - - - + + + + + +
2 - - - - - + + + + + +
1 - - - - - + + + + + +
0 - - - - - + + + + + +INH(µg/ml)
                                                                                                                                                            SQ109 (µg/ml)
 +  indicates growth,   -  indicates no growth,      Shaded boxes indicate  additivity between two drugs  
The combination of SQ109/RIF against Msmeg wild-type, decreased the MIC of SQ109 16-
fold in the presence of RIF, while the MIC of RIF was decreased 4-fold in the presence of 
SQ109 (Table 3.3). For the combination of SQ109/INH, the MIC of SQ109 was decreased 16-
fold in the presence of INH while the MIC of INH was decreased 8-fold in the presence of 
SQ109 (Table 3.4). 
The decrease in MIC of SQ109 was 1.5-fold and 4-fold for RIF in the SQ109 mutant 
(Table 3.5) similarly, the combination of SQ109/INH decreased the MIC of SQ109 1.5-fold 
while the MIC of INH decreased 4-fold (Table 3.6).The interaction study was performed on 
the SQ109-resistant mutant 1 only. 
The FICI was calculated by using the median between the highest concentration of the drug 
at which growth was observed and the lowest concentration at which growth was inhibited. 
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Table 3.7: Checkerboard synergy between SQ109/RIF and SQ109/INH Msmeg strains 





FIC  FICI Activity 
Wild-type SQ109 
RIF 
2.0 – 4.0 
0.5 – 1.0 
0.125 – 0.25 






2.0 – 4.0 
4.0 – 8.0 
0.125 – 0.25 






35 – 45 
2.0 – 4.0 
25 – 30 






35 – 45 
16 - 32 
25 – 30 





Synergistic effects were observed for SQ109/RIF and SQ109/INH combinations against 
Msmeg wild-type respectively, while the effect was additive for both SQ109/RIF and 
SQ109/INH combinations on SQ109-resistant mutant (Table 3.7). The synergistic effect 
between SQ109/RIF and SQ109/INH against Msmeg was also observed in a previous study 
(Reddy et al. 2010). 
3.7 Sanger sequencing of MSMEG_0250 in SQ109-resistant mutants 
A previous study demonstrated that mutations in mmpL3 of Mtb are associated with 
resistance to SQ109 (Tahlan et al. 2012). Msmeg contains a homologue of mmpL3, namely 
MSEG_0250. In order to determine if mutations in this gene were responsible for the 
resistance phenotypes of the 6 Msmeg mutants, four primer sets (Table 2.3) were designed 
to perform direct sequencing of this gene. A successful amplification was confirmed by 
agarose gel electrophoresis (Figure 6), and the PCR products were submitted for Sanger 
sequencing. The alignment of the sequence obtained for each PCR product with the 
sequence of MSMEG_0250 is shown in Figure 7. 
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Figure 3.6 a: Amplification of MSMEG_0250 gene by primer set 1. Lanes 1 – 6 contain product from DNA of six      
colonies, Lane 7 represents wild-type DNA performed as a positive control, Lane 8 is the negative control and 
M represents a 1 kb DNA marker. 
 
 
            M          1          2           3          4            5           6          7          8          M 
  
Figure 3.6 b: Amplification of MSMEG_0250 gene by primer set 2. Lanes 1 – 6 contain product from DNA of six      
colonies, Lane 7 represents wild-type DNA performed as a positive control, Lane 8 is the negative control (no 
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Figure 3.6 c: Amplification of MSMEG_0250 gene by primer set 3. Lanes 1 – 6 contain product from DNA of six 
colonies, Lane 7 represents wild-type DNA performed as a positive control, Lane 8 is the negative control and 
M represents a 1 kb DNA marker. 
 
 
    M         1          2           3            4            5          6           7          8        M 
  
Figure 3.6 d: Amplification of MSMEG_0250 gene by primer set 4. Lanes 1 – 6 contain product from DNA of six 
colonies, Lane 7 represents wild-type DNA performed as a positive control, Lane 8 is the negative control and 
M represents a 1 kb DNA marker. 
  730 bp 
  500 bp 
      750 bp 
      500 bp  
730 bp 
    750 bp 
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1 3,0422,224541 721 1,267
  
Figure 3.7: Alignment of sequence obtained for each primer set with the gene sequence of MSMEG_0250 
The sequence analysis of all PCR products of six isolated mutant strains did not reveal any 
mutation, therefore it is likely that other genes in Msmeg are involved in the resistance to 
SQ109. Whole genome sequencing was therefore performed to identify the mutations that 
confer this resistance. 
3.8 Identification of mutations in the genome of Msmeg SQ109-resistant mutants 
To determine genes that are involved in mutants of Msmeg being resistant to SQ109, 
genomic DNA was extracted from the six colonies and sent for sequencing. A number of 
single nucleotide polymorphisms (SNPs) were identified for each mutant. 
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Table 3.8: Genes involved in mutations of SQ109-resistant strains of Msmeg 
Mutant  SNPs genes Product Indels genes Product 
Mutant 1 MSMEG_4010 Glyoxalase family 
protein 
  
Mutant 2 MSMEG_5880 Nicotine 
dehydrogenase 
  

















































Mutant 5   MSMEG_5639 Enoyl-CoA 
hydratase 
Mutant 6 Intergenic region    
 
The identification of genes were done by mapping the sequencing reads of each mutant to 
the reference Msmeg genome and from there single-nucleotide polymorphisms (SNPs) and 
small insertions and deletions (indels) were identified by Genome Analysis ToolKit (GATK). 
No SNPs or indels were identified in the intergenic region for Mutant 6 (Table 3.8).  
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SQ109 is a promising new anti-TB drug that has shown synergistic activity with the current 
TB drugs, specifically with RIF and INH (Onajole et al. 2010). In this project, the mechanism 
of synergy of SQ109 with RIF and INH was studied in Msmeg. We hypothesised that the 
synergistic activity of SQ109 was due to inhibition of efflux in mycobacteria. Efflux systems 
are physiological mechanisms used by mycobacteria to defend themselves against toxic 
substances, including drugs, by extruding these compounds from the cells. These systems 
decrease the concentration of drugs in the cells and prevent them from reaching their 
targets. Inhibition of these efflux pumps increases the concentration of drugs in 
mycobacterial cells, thereby decreasing the concentration of drug required to kill them. This 
effect results in an apparent decrease in the MIC of the drug. 
The inhibitory concentrations of EtBr, verapamil, SQ109, RIF and INH for Msmeg were 
determined. MICs of EtBr, verapamil and SQ109 were in the same range as in the previous 
studies (Table 3.1) (Rodrigues et al. 2008, 2011; Reddy et al. 2010; Gupta and Bhakta 2012). 
For RIF and INH, the MIC values were different from those previously reported. The MIC of 
RIF in this study was determined to be between 0.5 – 1.0 µg/ml. In previous studies the MIC 
for RIF was reported to be 8.0 µg/ml or 1.0 µg/ml and the MIC for INH was reported to be 
8.0 µg/ml as well (Teng and Dick 2003; Reddy et al. 2010). The difference may be influenced 
by the media. Liquid culture was performed in 7H9 media supplemented with glucose-salt 
and in a previous study, 7H9 liquid medium was supplemented with albumin-dextrose-
catalase (ADC); this may affect the activity of the compounds against Msmeg. Drug-drug 
interaction studies in wild-type Msmeg confirmed the synergy previously reported between 
SQ109 and RIF or SQ109 and INH (Reddy et al. 2010). The fractional inhibitory concentration 
index (FICI) for the SQ109/RIF combination against Msmeg wild-type was higher compared 
to the literature, although it was still below the cut-off value of 0.5 for synergy (Table 3.7) 
(Reddy et al. 2010). The reason for this difference could be the time of exposure of 
mycobacterial cells to the drugs by incubating the plate for longer or shorter periods. During 
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drug interactions the plates were incubated for 6 to 7 days, while in the previous study the 
plates were read for 3 to 4 days. 
The effect of SQ109 on the EtBr efflux system was assessed by monitoring the rate of 
accumulation and efflux of EtBr in Msmeg. For the accumulation assay, an increase in 
fluorescence was observed with increasing EtBr concentrations. This is consistent with a 
previous study using a similar range of EtBr concentrations (Rodrigues et al. 2008; Jin et al. 
2010). Verapamil was found to increase EtBr accumulation in Msmeg (Figure 3.2 and 3.3), as 
observed previously (Jin et al. 2010; Rodrigues et al. 2011). This effect is thought to be 
caused by the inhibition of efflux pumps, although the target(s) of verapamil in 
mycobacteria are not known. Verapamil was used in our assays as a positive control 
compared to SQ109. The effect of SQ109 on EtBr accumulation and efflux in Msmeg 
produced inconsistent results. In some assays, SQ109 increase EtBr accumulation, to a lesser 
extent than verapamil, however this was not consistently observed (Figure 3.2 and 3.3). The 
effect of SQ109 was also assessed on RIF accumulation by measuring the concentrations of 
RIF in Msmeg. A significant increase of concentration of RIF in Msmeg was observed in the 
presence of verapamil, while in the presence of SQ109, the accumulation of RIF was similar 
to untreated cells (Figure 3.4). SQ109 therefore does not appear to influence RIF 
accumulation in Msmeg, however its effect on RIF accumulation in other mycobacteria 
cannot be inferred from this result. This therefore requires further investigation. et al.A 
previous study reported that Mtb strains harbouring mutations in mmpL3 were cross-
resistant to SQ109, suggesting that this transporter may be the target of SQ109 (Tahlan et 
al. 2012). MmpL3 is involved in transporting cell wall precursors across the cell membrane. 
It was therefore hypothesised that SQ109 increases the permeability of the cell wall 
allowing drugs to enter the cell more easily. This could account for the increase of RIF 
activity in the presence of SQ109 in Mtb shown in the literature (Daffé and Etienne 1999; 
Nikaido 2001). 
Spontaneous SQ109-resistant mutants of Msmeg were generated by selection on plates 
containing lethal concentrations of the drug. The Sanger DNA sequencing did not identify 
any mutations in MSMEG_0250 gene (mmpL3 homologue) (Figure 3.7), and this suggests 
that other genes may be involved in the resistance to SQ109 in Msmeg. In comparison to a 
previous work, spontaneous SQ109-resistant mutants could not be isolated in Mtb (Tahlan 
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et al. 2012). However, the generation of resistant mutants of Mtb to analogues of SQ109 
showed cross-resistance to SQ109 and the whole genome sequencing of these mutants 
identified mutations in then mmpL3 gene (Li et al. 2014). This suggests that the mechanism 
of resistance is different in the two species. This notion is supported by a recent study which 
reported that MmpL3 may not be the only target for SQ109 in Mtb (Li et al. 2014). 
An increase in MICs for SQ109, RIF and INH was demonstrated in an SQ109-resistant mutant 
of Msmeg. MIC values increased compared to the wild-type and this increase was 4-fold for 
RIF and INH and 20-fold for SQ109 (Table 3.2). For SQ109 the significant increase of MIC 
value may be a result of a decrease of drug affinity to its target, due to mutations that 
changed the structure of this target. The growth of each SQ109-resistant mutant strain of 
Msmeg was characterised in liquid medium and compared to the wild-type strain. No 
significant differences between the wild-type and mutant strains were observed 
(Figure 3.5), suggesting that the mutations present in these strains have no influence on the 
fitness of the bacteria under the conditions tested. 
Drug-drug interaction studies between SQ109, RIF or INH were conducted for SQ109-
resistant mutant 1 using the checkerboard method (K H Rand 1993; Reddy et al. 2010). The 
activity of two drugs in combination was assessed as synergistic, additive, indifferent or 
antagonistic. Our study demonstrated synergy between SQ109/RIF or SQ109/INH against 
wild-type of Msmeg with the fractional inhibitory concentration index (FICI) of 0.3125 and 
0.1875 respectively, and an additive activity in SQ109-resistant mutant strain with FICI value 
0.897 for both combinations (Table 3.7). The additive activity found in SQ109/RIF and 
SQ109/INH combinations against SQ109-resistant mutant suggests that SQ109 may have 
multiple targets within Msmeg. The mutation(s) present in SQ109-resistant mutant 1 has 
abolished the synergy of SQ109 with RIF and INH. However, the fact that additivity is now 
observed suggests that SQ109 has residual activity, which acts on another target.  
The whole genome sequencing of the six mutants identified genes that may be responsible 
for their resistance phenotype (Table 3.8). We did not investigate the link between these 
genes and mutations that confer resistance to SQ109 in Msmeg. However, further 
investigation will follow to confirm these mutations within these genes by Sanger DNA 
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sequencing and their role in SQ109 resistance and synergy with RIF and INH will be further 
investigated. 
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Conclusion 
 
This study investigated the influence of SQ109 on efflux in Msmeg, as a mechanism of its 
synergy with RIF and INH. Limitations associated with the methodology used to investigate 
the effect of SQ109 on efflux in Msmeg prevented us from drawing definitive conclusions 
from these experiments.. SQ109-resistant mutants of Msmeg did not harbour mutations in 
the MSMEG_0250 gene, suggesting that MmpL3 is not the target of SQ109 in Msmeg and 
that the mechanism of resistance is different from Mtb. The identification of SNPs and 
Indels in the genome of SQ109-resistant mutants suggests that SQ109 may have multiple 
targets in Msmeg, although the exact role of these SNPs and indels in resistance to SQ109 is 
yet to be determined. The knowledge of efflux systems, drug interactions and the molecular 
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